Christopher Reed’s Story

Christopher Reed headshot

J. Christopher Reed

Lupus Foundation of America-Georgia

Support Group Facilitator, Advocacy Chair

Christopher was diagnosed with lupus in 1990 at the age of 16. Lupus attacked his heart, lungs, kidneys, digestive system, veins, and nervous system. Christopher’s lupus journey began with chronic headaches and frequent muscle spasms then progressed to frequent fevers, arthritis, and tremendous weight loss. He was barely able wrap his hands around the steering wheels during driver’s ed class and walking up the stairwell to his bedroom felt like he was having a heart attack. In 2004, he developed stage 3 kidney disease.  With his first job out of law school, Christopher was juggling kidney disease and horrible chemotherapy treatments. In 2018, he almost lost his life due to septic shock.

Overtime, Christopher continued to suffer from severe organ involvement. He was constantly worried about a lack of insurance and the cost of his life-saving medication.

Despite these serious lupus attacks, and moving back to his parent’s home, Christopher earned a bachelor’s degree with honors from the Georgia State University and a law degree from Tulane University. He attributes his success to God, the support of family and the support received at an early age from the Lupus Foundation of America, Georgia Chapter (LFAGA).

In speaking with Christopher, one can tell he is an avid advocate passionate about tackling healthcare policy and increasing lupus research. He previously chaired the Georgia Council on Lupus Education and Awareness (Council), a sponsored entity created by the state legislature to improve the lives of Georgians living with lupus.  He has worked to establish the Georgia Lupus Collaborative, an advisory group and think tank charged with improving the lives of people with lupus in Georgia.

Christopher currently serves as a Support Group Facilitator, Advocacy Chair, and Project Manager for the Lupus Foundation of America-Georgia Chapter. His support group is specifically designed for men. As Advocacy Chair, he gives presentations on patient advocacy and public health policy as well as being a writer on Lupus. Each year, over a one hundred lupus advocates engage in Lupus Day at the Georgia State Capitol. He remains involved in Health Research and serves to increase African American participation in clinical trials through a series of education sessions, open discussion, and dialogues with African American physicians and African American researchers.

Christopher has been honored to be a recipient of several awards including the Mary Cann Achievement Award from the Lupus Foundation of America, Georgia Chapter.

The post Christopher Reed’s Story appeared first on Georgia Bio.

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS